The Microbiota-Gut-Brain Axis: A New Frontier in Precision Neuropsychopharmacology.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical literature without systematic review methodology.
PubMed 42316492 · doi:10.2174/011570159X438648260611062058
What was done
The authors conducted a narrative review of recent preclinical and clinical studies identified through PubMed, Scopus, and Web of Science. The review examined the mechanisms by which the gut microbiota influences the pharmacokinetics, pharmacodynamics, efficacy, and safety of psychotropic medications, specifically antidepressants, antipsychotics, mood stabilizers, and anxiolytics, as well as the potential role of microbiota-targeted adjuvant interventions.
What was found
The abstract reports no quantitative data or specific effect estimates. Mechanistically, gut microbes were reported to modulate psychotropic drug effects via enzymatic biotransformation, alteration of host metabolic pathways, regulation of neurotransmitter systems, and modulation of immune and endocrine signaling. Gut microbiota composition was associated with variability in clinical response and adverse-effect profiles. Adjuvant approaches such as probiotics, prebiotics, and dietary changes were identified as potential strategies to enhance drug efficacy and reduce side effects.
Why it matters
Understanding microbiota-drug interactions could eventually support personalized prescribing in psychiatry by explaining individual differences in drug responsiveness and side-effect vulnerability.
Limits
The underlying evidence is described as heterogeneous and largely associative. The field is constrained by methodological variability across studies, small sample sizes, and a lack of longitudinal clinical trials, preventing immediate translation of microbiota profiling into standard psychiatric practice.
Cited by
- contradicts Selective serotonin reuptake inhibitors (SSRIs) exert their clinical therapeutic effects by altering the gut microbiome to a favorable tryptophan-pathway microbiome rather than by blocking brain serotonin reuptake.